Company Description
Kyntra Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs.
The company is developing FG-3246, a potential antibody-drug conjugate targeting CD46, for the treatment of metastatic castration-resistant prostate cancer and other cancers.
It is also developing Roxadustat, a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.
The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. The company was formerly known as FibroGen, Inc. and change its name to Kyntra Bio, Inc. in January 2026.
Kyntra Bio, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
| Country | United States |
| Founded | 1993 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 34 |
| CEO | Thane Wettig |
Contact Details
Address: 350 Bay Street, Suite 100 #6009 San Francisco, California 94133 United States | |
| Phone | 415 978 1200 |
| Website | kyntrabio.com |
Stock Details
| Ticker Symbol | KYNB |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000921299 |
| CUSIP Number | 31572Q881 |
| ISIN Number | US31572Q8814 |
Key Executives
| Name | Position |
|---|---|
| Thane Wettig | Chief Executive Officer and Director |
| David DeLucia | Senior Vice President and Chief Financial Officer |
| John Alden | Corporate Secretary and General Counsel |
| Gaia Vasiliver-Shamis | Director of IR and Communications - LifeSci Advisors |